In addition, combined PI3K/mTOR and ERK inhibition can reverse therapeutic resistance in ovarian cancer cell lines, but the clinical efficacy of these agents requires further preclinical determination [228]. This evidence concerns the gene PIK3CB and ovarian cancer.